A Double-Blind Randomized Placebo-Controlled Study Assessing the Safety, Tolerability and Efficacy of a Herbal Medicine Containing Pycnogenol Combined with Papain and Aloe vera in the Prevention and Management of Pre-Diabetes
Open Access
- 22 April 2020
- Vol. 7 (4), 22
- https://doi.org/10.3390/medicines7040022
Abstract
Background: Herbal medicines present attractive options to patients with chronic diseases. Undertaking clinical studies with patients presenting with symptomless pre-T2D can lead to significant limitations. Methods: A 12-week randomized double-blind placebo-controlled clinical study was conducted that investigated the safety and efficacy of an herbal formulation administered orally for the treatment of pre-type 2 diabetes (pre-T2D). Results: A numerically greater proportion of subjects in the interventional arm had impaired fasting glucose (IFG) at week 12 compared to the control arm (71.0% vs. 69.0%, p = 0.75). Fewer participants had impaired glucose tolerance (IGT) at 12 weeks in the intervention arm compared to the control arm (unadjusted 58.3% vs. 66.7%, p = 0.65; adjusting for baseline IGT, p = 0.266). In a subgroup analysis, subjects with a baseline fasting plasma glucose (FPG) level in the range of 6.1–6.9 mmol/L demonstrated a non-significant lower proportion of IFG at week 12 in the intervention arm compared to the control arm (60.0% vs. 41.7% p = 0.343). Total blood cholesterol and triglyceride levels remained unchanged from baseline to week 12 in both treatment groups. Conclusions: This study suggests that a polyherbal medicine was not effective for reducing the metabolic markers associated with pre-T2D over a 12-week period. Therefore, larger studies with well-defined endpoints and of longer duration are warranted.Keywords
This publication has 33 references indexed in Scilit:
- Gut metagenome in European women with normal, impaired and diabetic glucose controlNature, 2013
- Effects ofAloe veraSupplementation in Subjects with Prediabetes/Metabolic SyndromeMetabolic Syndrome and Related Disorders, 2013
- Setting up a community oral glucose tolerance testing servicePrimary Health Care, 2010
- Glucose Indices, Health Behaviors, and Incidence of Diabetes in AustraliaDiabetes Care, 2008
- Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysisBMJ, 2007
- Contributions of β-Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting GlucoseDiabetes Care, 2006
- Point: Impaired Fasting Glucose: The Case for the New American Diabetes Association CriterionDiabetes Care, 2006
- Point: Impaired Fasting Glucose: The Case for the New American Diabetes Association CriterionDiabetes Care, 2006
- Contributions of -Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting GlucoseDiabetes Care, 2006
- Antidiabetic effect of Pycnogenol® French maritime pine bark extract in patients with diabetes type IILife Sciences, 2004